Mostrar el registro sencillo del ítem
dc.contributor.author
Aris, Mariana
dc.contributor.author
Mordoh, Jose
dc.contributor.author
Barrio, Maria Marcela
dc.date.available
2019-05-06T19:24:49Z
dc.date.issued
2017-08
dc.identifier.citation
Aris, Mariana; Mordoh, Jose; Barrio, Maria Marcela; Immunomodulatory monoclonal antibodies in combined immunotherapy trials for cutaneous melanoma; Frontiers Media S.A.; Frontiers in Immunology; 8; AUG; 8-2017; 1-15
dc.identifier.issn
1664-3224
dc.identifier.uri
http://hdl.handle.net/11336/75657
dc.description.abstract
In the last few years, there has been a twist in cancer treatment toward immunotherapy thanks to the impressive results seen in advanced patients from several tumor pathologies. Cutaneous melanoma is a highly mutated and immunogenic tumor that has been a test field for the development of immunotherapy. However, there is still a way on the road to achieving complete and long-lasting responses in most patients. It is desirable that immunotherapeutic strategies induce diverse immune reactivity specific to tumor antigens, including the so-called neoantigens, as well as the blockade of immunosuppressive mechanisms. In this review, we will go through the role of promising monoclonal antibodies in cancer immunotherapy with immunomodulatory function, especially blocking of the inhibitory immune checkpoints CTLA-4 and PD-1, in combination with different immunotherapeutic strategies such as vaccines. We will discuss the rational basis for these combinatorial approaches as well as different schemes currently under study for cutaneous melanoma in the clinical trials arena. In this way, the combination of "push and release" immunomodulatory therapies can contribute to achieving a more robust and durable antitumor immune response in patients.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Frontiers Media S.A.
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Clinical Trials
dc.subject
Combined Tumor Immunotherapy
dc.subject
Cutaneous Melanoma
dc.subject
Immune Checkpoint Blockade
dc.subject
Monoclonal Antibodies
dc.subject.classification
Medicina Critica y de Emergencia
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Immunomodulatory monoclonal antibodies in combined immunotherapy trials for cutaneous melanoma
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2019-05-06T18:19:16Z
dc.journal.volume
8
dc.journal.number
AUG
dc.journal.pagination
1-15
dc.journal.pais
Suiza
dc.journal.ciudad
Laussane
dc.description.fil
Fil: Aris, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.description.fil
Fil: Mordoh, Jose. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Instituto Leloir; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina. Instituto Alexander Fleming; Argentina
dc.description.fil
Fil: Barrio, Maria Marcela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Cáncer. Centro de Investigaciones Oncológicas; Argentina
dc.journal.title
Frontiers in Immunology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fimmu.2017.01024
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2017.01024
Archivos asociados